Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

2 clinical studies listed.

Filters:

Germline Mutations

Tundra lists 2 Germline Mutations clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ENROLLING BY INVITATION

NCT06917794

Development of Polygenic Risk Scores in Colon Cancer Patients Through the Study of Ancestry and Diversity in Genetic Maps of the Brazilian Population - ORIGEM Project

Development of a polygenic risk score based on somatic and germline genetic information from patients with colorectal cancer

Gender: All

Ages: 18 Years - Any

Updated: 2025-04-08

7 states

Colo-rectal Cancer
Polygenic Risk Score
Somatic Mutation
+3
RECRUITING

NCT01994057

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

For patients of advanced NSCLC (non small cell lung cancer) , Individualized cancer therapy has been widely accepted since the success of crizotinib administration based on EML4-ALK fusion gene detection and gefitinib and erlotinib administration based on EGFR-TKIs sensitive mutations.From clinical points of view ,individual differences often occur between different patients, leading diverse effect in ADR and drug effect.Meanwhile ,the drug effect and adverse drug reaction was significantly influenced by the pharmacokinetic factors and pharmacodynamic factors.In this research ,we try to establish a more sensitive method to detect sensitive mutations in plasma and discover the correlation between somatic and germline mutations , trough concentration and EGFR-TKI drug effect, the association between ADME-associated SNP ,trough concentration and EGFR-TKI adverse effect .Furthermore, in vivo and in vitro research is also crucial for rational explanation for these clinical phenomenon.

Gender: All

Ages: 18 Years - 85 Years

Updated: 2023-04-12

1 state

Non-small Cell Lung Cancer (NSCLC)
EGFR-TKI Resistant Mutation
EGFR-TKI Sensitizing Mutation
+2